Alethia Biotherapeutics   Report issue

For profit Phase 2
Founded: Montreal Canada (2002)

Organization Overview

First Clinical Trial
2015
NCT02412462
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alethia Biotherapeutics | Alethia Biotherapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

ab-16b5 (2 trials)

docetaxel (taxotere) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2